Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

Last updated: October 30, 2024
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chemotherapy

Carcinoma

Treatment

Stereotactic body radiotherapy

Clinical Study ID

NCT06595108
09-2024-0026
  • Ages 19-80
  • All Genders

Study Summary

To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy.

In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 19 to 80 years old

  2. Liver function Child-Pugh class A

  3. ECOG 0-1

  4. Patient clinically or pathologically diagnosed with hepatocellular carcinoma

  5. Advanced hepatocellular carcinoma that is inoperable

  6. Satisfies the dose limits for normal organs and lesions of an appropriate size to beincluded in the scope of radiotherapy.

Exclusion

Exclusion Criteria:

  1. Brain metastases

  2. Have a history of malignancy other than hepatocellular carcinoma within the last 5years (except for malignancies with little risk of metastasis or death, e.g.,adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localizedprostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)

  3. Subjects with a high probability of untreated gastric or esophageal varices orbleeding

  4. Serious uncontrolled medical comorbidities

  5. History of liver transplant surgery

  6. Autoimmune liver disease

Study Design

Total Participants: 33
Treatment Group(s): 1
Primary Treatment: Stereotactic body radiotherapy
Phase:
Study Start date:
May 28, 2024
Estimated Completion Date:
March 27, 2028

Study Description

The subjects with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and if they voluntarily agree to the clinical trial after explanation of the clinical trial, they are included in the clinical trial. Subjects should begin SBRT(stereotactic body radiotherapy) to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.

The followings are evaluation items for each visit.

Visit 1 (-6~0 weeks) ± 7days *Screening

  • Informed consent form

  • Inclusion Criteria/ Exclusion Criteria

  • Medical history and physical examination

  • Staging via CT, MRI, PET-CT, etc. (PET-CT examination is not compulsory)

  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers

  • Stool microbiota NGS

  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 2 (0~7 weeks) ± 7 days *During SBRT

  • Confirmation of adverse events

  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 3 (1~8 weeks) *1 week after SBRT

  • Confirmation of adverse events

  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers

  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 4 (6~9 weeks) ± 7 days *After 2 cycles of chemotherapy

  • Confirmation of adverse events

  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers

  • Stool microbiota NGS

  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit: 512 (336 months) ± 2 weeks *Follow-up

  • Confirmation of adverse events

  • Evaluation of effectiveness* (Imaging tests, Tumor markers, CBC, SMA, PT/aPTT are performed according to the need)

  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Connect with a study center

  • Yongin Severance Hospital

    Yongin-si, 365
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.